Idiopathic Intracranial Hypertension Workup
- Author: Mark S Gans, MD; Chief Editor: Andrew G Lee, MD more...
Blood tests are useful for ruling out systemic lupus erythematosus or other collagen-vascular diseases, which have been reported as underlying conditions in some patients who present with idiopathic intracranial hypertension (IIH).
An increased incidence of anticardiolipin antibodies has been reported in patients with IIH. Accordingly, some authors advocate anticardiolipin antibody assessment in all IIH patients, regardless of prior history of thrombosis. Some authors advocate screening for anticardiolipin antibodies and other procoagulant states in all patients with IIH who are either male or nonobese.
Cases of IIH associated with Lyme disease have been reported.
Most patients with typical history, gender, and body habitus need only routine blood work, if any. Recommended blood tests include the following:
Complete blood count (CBC)
Erythrocyte sedimentation rate (ESR)
Serum iron and iron-binding capacity
Antinuclear antigen (ANA) profile (eg, anti-dsDNA and anti-ssDNA)
Full procoagulant profile, including protein S, protein C, homocysteine levels, antithrombin III, factor V Leiden variant, antiphospholipid/anticardiolipin antibodies, lupus anticoagulant, and platelet aggregation studies (in patients with a previous history of thrombosis or MRI evidence of dural venous sinus occlusion on magnetic resonance imaging [MRI])
Lyme screening test (enzyme-linked immunosorbent assay [ELISA]) in patients who have a history of exposure to Lyme in areas of endemic disease
CSF studies include the following:
White blood cell (WBC) and differential counts
Red blood cell (RBC) count
Quantitative protein electrophoresis
Aerobic bacterial culture and sensitivity
Acid-fast bacilli (AFB) culture
Cryptococcal antigen (especially in patients with HIV)
Syphilis markers (eg, rapid plasma reagin [RPR])
Tumor markers and cytology (in patients with a history of cancer or with clinical features suggesting occult malignancy)
Most patients with typical history, gender, and body habitus need only routine CSF tests. However, extra fluid should be frozen in case the preliminary workup reveals unexpected abnormalities such as pleocytosis or elevated gamma globulin, which would indicate that more complete investigation for autoimmune, infectious, or neoplastic conditions is warranted.
MRI and CT
A patient with bilateral disc swelling should undergo urgent neuroimaging studies to rule out an intracranial mass or a dural sinus thrombosis. In the setting of IIH, the findings on neuroimaging studies include normal or small slitlike ventricles, enlarged optic nerve sheaths, and, occasionally, an empty sella.
MRI of the brain with gadolinium enhancement is probably the study of choice for all patients with IIH, in that it provides sensitive screening for hydrocephalus, intracerebral masses, meningeal infiltrative or inflammatory disease, and dural venous sinus thrombosis. In a retrospective study of imaging features that have been suggested as typical for patients with IIH, only flattening of the posterior globe was found to be a reliable indicator of IIH, with a specificity of 100% and a sensitivity of 43.5%.
MR venography can be useful for patients who are at greater risk for dural venous sinus thrombosis, such as those with suspected thrombosis on MRI, nonobese or male individuals, or those with a documented procoagulant state. Sagittal T1-weighted images often provide excellent views of the superior sagittal sinus, and these typically are included in routine MRI. Extraluminal narrowing of the transverse sinuses may be a typical feature of IIH, as reported by Farb et al.
Computed tomography (CT) of the brain is less expensive than MRI and is adequate to rule out an intracranial lesion in most instances; however, MRI and magnetic resonance (MR) venography are more effective in ruling out a mass lesion and a dural sinus thrombosis, respectively. Although MR venography was once considered an elective imaging study for atypical patients, it is now increasingly accepted as a routine study for all patients with IIH.
Bedside ultrasonography has been used to identify intracranial hypertension by precisely measuring the diameter of the optic nerve sheath. If this diameter increases in primary gaze and diminishes by 25% in eccentric gaze (30° test), then increased subarachnoid fluid surrounding the optic nerve is presumably present. This finding is consistent with papilledema if it is bilateral.
The drawback of this noninvasive technique is that it requires a highly skilled clinician to obtain reproducible results.
Once an intracranial mass lesion is ruled out, lumbar puncture is indicated. The opening pressure should be measured with the patient relaxed in the decubitus position to prevent a falsely elevated pressure reading. If any specific difficulty was encountered that may have caused such as false elevation, the clinician performing the procedure must communicate this to the ophthalmologist. Unfortunately, some patients demonstrate a transiently normal pressure despite harboring IIH; confirming the disease in these patients is difficult.
Besides the value of the opening pressure, the clarity and the color of the cerebrospinal fluid should be noted. In addition, the cerebrospinal fluid (CSF) should be forwarded for cell count, cytology, culture, and measurement of glucose, protein, and electrolyte concentrations. All of these findings are normal in patients with IIH.
In obese patients, finding landmarks may be difficult; consequently, the tap is often performed with the patient seated. It should be kept in mind that the normal CSF pressure at the foramen magnum in the seated position is nearly 500 mm water from the lumbar entry point in persons of average height. Thus, an opening pressure of 500 mm water is extremely high for the lateral decubitus position but normal for the sitting position. If possible, the patient should be moved to the lateral decubitus position before the pressure is measured.
Another approach to lumbar puncture in obese patients utilizes fluoroscopic guidance in the radiology department. The prone positioning on the x-ray table and the increased abdominal pressure in this position may elevate the CSF pressure falsely. If the pressure is normal with the patient in the prone position, then the measurement is probably accurate. However, if it is high, the patient must be rolled into the lateral decubitus position and allowed to relax before a reliable pressure reading can be completed.
Obviously, such maneuvers carry a risk of displacing the needle from the thecal space. However, no alternative method exists for obtaining an accurate pressure reading.
Jindal M, Hiam L, Raman A, Rejali D. Idiopathic intracranial hypertension in otolaryngology. Eur Arch Otorhinolaryngol. 2009 Jun. 266(6):803-6. [Medline].
Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri). Curr Neurol Neurosci Rep. 2008 Mar. 8(2):87-93. [Medline].
Feldon SE. Visual outcomes comparing surgical techniques for management of severe idiopathic intracranial hypertension. Neurosurg Focus. 2007. 23(5):E6. [Medline].
Friedman DI, Jacobson DM. Idiopathic intracranial hypertension. J Neuroophthalmol. 2004 Jun. 24(2):138-45. [Medline].
Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology. 2002 Nov 26. 59(10):1492-5. [Medline].
Miller NR, Newman NJ. Pseudotumor cerebri (benign intracranial hypertension). In:. Walsh and Hoyt’s Clinical Neuro-Ophthalmology. Vol 1. 5th ed. 1999:523-38.:
Bateman GA, Stevens SA, Stimpson J. A mathematical model of idiopathic intracranial hypertension incorporating increased arterial inflow and variable venous outflow collapsibility. J Neurosurg. 2009 Mar. 110(3):446-56. [Medline].
Farb RI, Vanek I, Scott JN, Mikulis DJ, Willinsky RA, Tomlinson G, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology. 2003 May 13. 60(9):1418-24. [Medline].
Bateman GA. Association between arterial inflow and venous outflow in idiopathic and secondary intracranial hypertension. J Clin Neurosci. 2006 Jun. 13(5):550-6; discussion 557. [Medline].
Bateman GA. Arterial inflow and venous outflow in idiopathic intracranial hypertension associated with venous outflow stenoses. J Clin Neurosci. 2008 Apr. 15(4):402-8. [Medline].
Corbett JJ. The first Jacobson Lecture. Familial idiopathic intracranial hypertension. J Neuroophthalmol. 2008 Dec. 28(4):337-47. [Medline].
Daniels AB, Liu GT, Volpe NJ, Galetta SL, Moster ML, Newman NJ, et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol. 2007 Apr. 143(4):635-41. [Medline].
Radhakrishnan K, Ahlskog JE, Garrity JA, Kurland LT. Idiopathic intracranial hypertension. Mayo Clin Proc. 1994 Feb. 69(2):169-80. [Medline].
Rogers AH, Rogers GL, Bremer DL, McGregor ML. Pseudotumor cerebri in children receiving recombinant human growth hormone. Ophthalmology. 1999 Jun. 106(6):1186-9; discussion 1189-90. [Medline].
Howell SJ, Wilton P, Shalet SM. Growth hormone replacement in patients with Langerhan's cell histiocytosis. Arch Dis Child. 1998 May. 78(5):469-73. [Medline]. [Full Text].
Crock PA, McKenzie JD, Nicoll AM, Howard NJ, Cutfield W, Shield LK, et al. Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand. Acta Paediatr. 1998 Apr. 87(4):381-6. [Medline].
Williams JB. Adverse effects of thyroid hormones. Drugs Aging. 1997 Dec. 11(6):460-9. [Medline].
Raghavan S, DiMartino-Nardi J, Saenger P, Linder B. Pseudotumor cerebri in an infant after L-thyroxine therapy for transient neonatal hypothyroidism. J Pediatr. 1997 Mar. 130(3):478-80. [Medline].
Sacchi S, Russo D, Avvisati G, Dastoli G, Lazzarino M, Pelicci PG, et al. All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi). Haematologica. 1997 Jan-Feb. 82(1):106-21. [Medline].
Visani G, Bontempo G, Manfroi S, Pazzaglia A, D'Alessandro R, Tura S. All-trans-retinoic acid and pseudotumor cerebri in a young adult with acute promyelocytic leukemia: a possible disease association. Haematologica. 1996 Mar-Apr. 81(2):152-4. [Medline].
Selleri C, Pane F, Notaro R, Catalano L, Santoro LE, Luciano L, et al. All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukaemia followed by ATRA-induced pseudotumour cerebri. Br J Haematol. 1996 Mar. 92(4):937-40. [Medline].
Ahmad S. Amiodarone and reversible benign intracranial hypertension. Cardiology. 1996 Jan-Feb. 87(1):90. [Medline].
Varadi G, Lossos A, Or R, Kapelushnik J, Nagler A. Successful allogeneic bone marrow transplantation in a patient with ATRA-induced pseudotumor cerebri. Am J Hematol. 1995 Oct. 50(2):147-8. [Medline].
Sivin I. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System. Obstet Gynecol. 1995 Aug. 86(2):318-20. [Medline].
Baqui AH, de Francisco A, Arifeen SE, Siddique AK, Sack RB. Bulging fontanelle after supplementation with 25,000 IU of vitamin A in infancy using immunization contacts. Acta Paediatr. 1995 Aug. 84(8):863-6. [Medline].
Alder JB, Fraunfelder FT, Edwards R. Levonorgestrel implants and intracranial hypertension. N Engl J Med. 1995 Jun 22. 332(25):1720-1. [Medline].
Malozowski S, Tanner LA, Wysowski DK, Fleming GA, Stadel BV. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr. 1995 Jun. 126(6):996-9. [Medline].
Campos SP, Olitsky S. Idiopathic intracranial hypertension after L-thyroxine therapy for acquired primary hypothyroidism. Clin Pediatr (Phila). 1995 Jun. 34(6):334-7. [Medline].
Nasr SZ, Schaffert D. Symptomatic increase in intracranial pressure following pancreatic enzyme replacement therapy for cystic fibrosis. Pediatr Pulmonol. 1995 Jun. 19(6):396-7. [Medline].
Price DA, Clayton PE, Lloyd IC. Benign intracranial hypertension induced by growth hormone treatment. Lancet. 1995 Feb 18. 345(8947):458-9. [Medline].
Kelly SJ, O'Donnell T, Fleming JC, Einhaus S. Pseudotumor cerebri associated with lithium use in an 11-year-old boy. J AAPOS. 2009 Apr. 13(2):204-6. [Medline].
Mollan SP, Ball AK, Sinclair AJ, Madill SA, Clarke CE, Jacks AS, et al. Idiopathic intracranial hypertension associated with iron deficiency anaemia: a lesson for management. Eur Neurol. 2009. 62(2):105-8. [Medline].
Lin A, Foroozan R, Danesh-Meyer HV, De Salvo G, Savino PJ, Sergott RC. Occurrence of cerebral venous sinus thrombosis in patients with presumed idiopathic intracranial hypertension. Ophthalmology. 2006 Dec. 113(12):2281-4. [Medline].
Kesler A, Yatziv Y, Shapira I, Berliner S, Assayag EB. Increased red blood cell aggregation in patients with idiopathic intracranial hypertension. A hitherto unexplored pathophysiological pathway. Thromb Haemost. 2006 Oct. 96(4):483-7. [Medline].
Warner JE, Larson AJ, Bhosale P, Digre KB, Henley C, Alder SC, et al. Retinol-binding protein and retinol analysis in cerebrospinal fluid and serum of patients with and without idiopathic intracranial hypertension. J Neuroophthalmol. 2007 Dec. 27(4):258-62. [Medline].
Fraser JA, Bruce BB, Rucker J, Fraser LA, Atkins EJ, Newman NJ, et al. Risk factors for idiopathic intracranial hypertension in men: a case-control study. J Neurol Sci. 2010 Mar 15. 290(1-2):86-9. [Medline]. [Full Text].
Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol. 1988 Aug. 45(8):875-7. [Medline].
Radhakrishnan K, Ahlskog JE, Cross SA, Kurland LT, O'Fallon WM. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol. 1993 Jan. 50(1):78-80. [Medline].
Radhakrishnan K, Thacker AK, Bohlaga NH, Maloo JC, Gerryo SE. Epidemiology of idiopathic intracranial hypertension: a prospective and case-control study. J Neurol Sci. 1993 May. 116(1):18-28. [Medline].
Jirásková N, Rozsíval P. Idiopathic intracranial hypertension in pediatric patients. Clin Ophthalmol. 2008 Dec. 2(4):723-6. [Medline]. [Full Text].
Bruce BB, Kedar S, Van Stavern GP, Monaghan D, Acierno MD, Braswell RA, et al. Idiopathic intracranial hypertension in men. Neurology. 2009 Jan 27. 72(4):304-9. [Medline]. [Full Text].
Digre KB, Nakamoto BK, Warner JE, Langeberg WJ, Baggaley SK, Katz BJ. A comparison of idiopathic intracranial hypertension with and without papilledema. Headache. 2009 Feb. 49(2):185-93. [Medline].
Corbett JJ, Savino PJ, Thompson HS, Kansu T, Schatz NJ, Orr LS, et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol. 1982 Aug. 39(8):461-74. [Medline].
Agostoni E, Aliprandi A. Alterations in the cerebral venous circulation as a cause of headache. Neurol Sci. 2009 May. 30 Suppl 1:S7-10. [Medline].
Ney JJ, Volpe NJ, Liu GT, Balcer LJ, Moster ML, Galetta SL. Functional visual loss in idiopathic intracranial hypertension. Ophthalmology. 2009 Sep. 116(9):1808-1813.e1. [Medline].
Wall M, George D. Visual loss in pseudotumor cerebri. Incidence and defects related to visual field strategy. Arch Neurol. 1987 Feb. 44(2):170-5. [Medline].
Shah VA, Kardon RH, Lee AG, Corbett JJ, Wall M. Long-term follow-up of idiopathic intracranial hypertension: the Iowa experience. Neurology. 2008 Feb 19. 70(8):634-40. [Medline].
Kupersmith MJ, Gamell L, Turbin R, Peck V, Spiegel P, Wall M. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology. 1998 Apr. 50(4):1094-8. [Medline].
Rowe FJ, Sarkies NJ. Assessment of visual function in idiopathic intracranial hypertension: a prospective study. Eye (Lond). 1998. 12 ( Pt 1):111-8. [Medline].
Sugerman HJ, Felton WL 3rd, Salvant JB Jr, Sismanis A, Kellum JM. Effects of surgically induced weight loss on idiopathic intracranial hypertension in morbid obesity. Neurology. 1995 Sep. 45(9):1655-9. [Medline].
Sugerman HJ, Felton WL 3rd, Sismanis A, Kellum JM, DeMaria EJ, Sugerman EL. Gastric surgery for pseudotumor cerebri associated with severe obesity. Ann Surg. 1999 May. 229(5):634-40; discussion 640-2. [Medline]. [Full Text].
González-Hernández A, Fabre-Pi O, Díaz-Nicolás S, López-Fernández JC, López-Veloso C, Jiménez-Mateos A. [Headache in idiopathic intracranial hypertension]. Rev Neurol. 2009 Jul 1-15. 49(1):17-20. [Medline].
Nampoory MR, Johny KV, Gupta RK, Constandi JN, Nair MP, al-Muzeiri I. Treatable intracranial hypertension in patients with lupus nephritis. Lupus. 1997. 6(7):597-602. [Medline].
Leker RR, Steiner I. Anticardiolipin antibodies are frequently present in patients with idiopathic intracranial hypertension. Arch Neurol. 1998 Jun. 55(6):817-20. [Medline].
Sussman J, Leach M, Greaves M, Malia R, Davies-Jones GA. Potentially prothrombotic abnormalities of coagulation in benign intracranial hypertension. J Neurol Neurosurg Psychiatry. 1997 Mar. 62(3):229-33. [Medline]. [Full Text].
Bachman DT, Srivastava G. Emergency department presentations of Lyme disease in children. Pediatr Emerg Care. 1998 Oct. 14(5):356-61. [Medline].
Agid R, Farb RI, Willinsky RA, Mikulis DJ, Tomlinson G. Idiopathic intracranial hypertension: the validity of cross-sectional neuroimaging signs. Neuroradiology. 2006 Aug. 48(8):521-7. [Medline].
Maralani PJ, Hassanlou M, Torres C, Chakraborty S, Kingstone M, Patel V, et al. Accuracy of brain imaging in the diagnosis of idiopathic intracranial hypertension. Clin Radiol. 2012 Jul. 67(7):656-63. [Medline].
Stone MB. Ultrasound diagnosis of papilledema and increased intracranial pressure in pseudotumor cerebri. Am J Emerg Med. 2009 Mar. 27(3):376.e1-376.e2. [Medline].
Szewka AJ, Bruce BB, Newman NJ, Biousse V. Idiopathic Intracranial Hypertension: Relation Between Obesity and Visual Outcomes. J Neuroophthalmol. 2012 Jan 3. [Medline]. [Full Text].
Digre KB, Varner MW, Corbett JJ. Pseudotumor cerebri and pregnancy. Neurology. 1984 Jun. 34(6):721-9. [Medline].
Giuseffi V, Wall M, Siegel PZ, Rojas PB. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study. Neurology. 1991 Feb. 41(2 ( Pt 1)):239-44. [Medline].
Hughes S. Drug Improves Vision in Idiopathic Intracranial Hypertension. Medscape Medical News. Available at http://www.medscape.com/viewarticle/824073. Accessed: April 29, 2014.
Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014 Apr 23-30. 311(16):1641-51. [Medline].
Goh KY, Schatz NJ, Glaser JS. Optic nerve sheath fenestration for pseudotumor cerebri. J Neuroophthalmol. 1997 Jun. 17(2):86-91. [Medline].
Brazis PW. Clinical review: the surgical treatment of idiopathic pseudotumour cerebri (idiopathic intracranial hypertension). Cephalalgia. 2008 Dec. 28(12):1361-73. [Medline].
Chandrasekaran S, McCluskey P, Minassian D, Assaad N. Visual outcomes for optic nerve sheath fenestration in pseudotumour cerebri and related conditions. Clin Experiment Ophthalmol. 2006 Sep-Oct. 34(7):661-5. [Medline].
Spoor TC, McHenry JG. Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol. 1993 May. 111(5):632-5. [Medline].
Nithyanandam S, Manayath GJ, Battu RR. Optic nerve sheath decompression for visual loss in intracranial hypertension: report from a tertiary care center in South India. Indian J Ophthalmol. 2008 Mar-Apr. 56(2):115-20. [Medline]. [Full Text].
Yadav YR, Parihar V, Agarwal M, Bhatele PR, Saxena N. Lumbar peritoneal shunt in idiopathic intracranial hypertension. Turk Neurosurg. 2012. 22(1):21-6. [Medline].
Burgett RA, Purvin VA, Kawasaki A. Lumboperitoneal shunting for pseudotumor cerebri. Neurology. 1997 Sep. 49(3):734-9. [Medline].
Woodworth GF, McGirt MJ, Elfert P, Sciubba DM, Rigamonti D. Frameless stereotactic ventricular shunt placement for idiopathic intracranial hypertension. Stereotact Funct Neurosurg. 2005. 83(1):12-6. [Medline].
Sinclair AJ, Kuruvath S, Sen D, Nightingale PG, Burdon MA, Flint G. Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. Cephalalgia. 2011 Dec. 31(16):1627-33. [Medline].
Bussière M, Falero R, Nicolle D, Proulx A, Patel V, Pelz D. Unilateral transverse sinus stenting of patients with idiopathic intracranial hypertension. AJNR Am J Neuroradiol. 2010 Apr. 31(4):645-50. [Medline].
Arac A, Lee M, Steinberg GK, Marcellus M, Marks MP. Efficacy of endovascular stenting in dural venous sinus stenosis for the treatment of idiopathic intracranial hypertension. Neurosurg Focus. 2009 Nov. 27(5):E14. [Medline].
Fridley J, Foroozan R, Sherman V, Brandt ML, Yoshor D. Bariatric surgery for the treatment of idiopathic intracranial hypertension. J Neurosurg. 2011 Jan. 114(1):34-9. [Medline].
Johnson LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. 1998 Dec. 105(12):2313-7. [Medline].
Pollak L, Zohar E, Glovinsky Y, Huna-Baron R. Reevaluation of presentation and course of idiopathic intracranial hypertension - a large cohort comprehensive study. Acta Neurol Scand. 2012 Dec 31. [Medline].